BioLineRx Ltd.
BLRX
$3.61
-$0.24-6.23%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -176.85% | 260.87% | 45.26% | -1,302.89% | 169.54% |
Total Depreciation and Amortization | 6.67% | -90.73% | 111.79% | 76.47% | -46.93% |
Total Amortization of Deferred Charges | -100.00% | -5.39% | -- | -- | -- |
Total Other Non-Cash Items | 121.27% | -7.14% | -434.71% | 75.40% | -61.78% |
Change in Net Operating Assets | 464.52% | -25.12% | 88.06% | 52.33% | 33.11% |
Cash from Operations | 93.17% | 69.91% | 12.37% | 13.28% | 19.70% |
Capital Expenditure | -- | -- | -- | 100.00% | 15.63% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 54.57% | -173.33% | 9.59% | 218.07% | -151.55% |
Cash from Investing | 54.70% | -173.29% | 9.65% | 217.70% | -151.81% |
Total Debt Issued | -- | -- | -- | -100.00% | -- |
Total Debt Repaid | -0.64% | 89.70% | -1,065.99% | -14.19% | -1.68% |
Issuance of Common Stock | -73.29% | -2.70% | -- | -- | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -83.05% | 952.12% | 8.95% | -105.10% | 2,771.03% |
Foreign Exchange rate Adjustments | 626.83% | -150.62% | 100.00% | 129.78% | -633.33% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -31.93% | -187.50% | 303.30% | -121.66% | 109.39% |